Does genetic risk help to predict amyloid burden in a non-demented population? A Bayesian approach
Year: 2017
Type: preprint
Abstract: INTRODUCTION In this study we investigate the association between A β levels in cerebrospinal fluid (CSF) and genetic risk in a non-demented population. This paper presents the first analysis to use a Bayesian methodology in this area. METHODS Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the EDAR* and DESCRIPA** studies was used in a Bayesian logistic regression analysis. We modeled CSF A β burden using age, diagnosis (healthy control or mild cognitive impairment), APOE and a polygenic risk score (PGRS) associated with Alzheimer’s Disease (AD). We compared models built using informative priors on age, diagnosis and APOE with non-informative priors on all variables. RESULTS The use of informative priors did not improve model performance in the majority of cases. Models using only age, diagnosis and APOE genotype showed the best predictive ability. DISCUSSION A previous study indicated that a PGRS of AD case/control status was associated with CSF A β burden in healthy controls. The current study suggests that this association does not lead to models that are more predictive of amyloid positivity than already known factors such as age and APOE . *‘Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response’ **‘Development of screening guidelines and criteria for pre-dementia Alzheimers disease’
DOI: 10.1101/174995
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Bristol-Myers Squibb, Alzheimer's Drug Discovery Foundation, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Novartis Pharmaceuticals Corporation, National Institute for Social Care and Health Research, South London and Maudsley NHS Foundation Trust, Northern California Institute for Research and Education, Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, Alzheimer's Society, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, King's College London, University College London, European Commission, Eisai, Innovative Medicines Initiative, Servier, H. Lundbeck A/S, IXICO, National Institutes of Health, Genentech, University of California, San Diego, Canadian Institutes of Health Research, Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering, Johnson and Johnson Pharmaceutical Research and Development, Janssen Alzheimer Immunotherapy Research And Development
Awards: G1012222616, G160417252, G1877862647, Centre for Health service and Academic Partnership in Translational eHealth Research (CHAPTER), G2423387114, G2522063444, G2835601961, G29951154, G3146424788, G3207356259, G3335867693, G3870774570, G393177772, G3966393351, G4119534169, G4196769506, G4401988282, G4457630332, G4475667458, G4860885537, G5324093878, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", G5702163051, Alzheimer's Disease Neuroimaging Initiative, Early identification of Alzheimer's disease: dynamic biomarkers for enrichment of trials, G6382720711, G7511831505, European Medical Information Framework, G8601545330, G9000074849, G9000122335, G920654007
OpenAlex ID: W2744740906
